JP2018520173A - コレカルシフェロール硫酸塩及びビタミンd欠乏症の処置のためのこれらの使用 - Google Patents
コレカルシフェロール硫酸塩及びビタミンd欠乏症の処置のためのこれらの使用 Download PDFInfo
- Publication number
- JP2018520173A JP2018520173A JP2018500894A JP2018500894A JP2018520173A JP 2018520173 A JP2018520173 A JP 2018520173A JP 2018500894 A JP2018500894 A JP 2018500894A JP 2018500894 A JP2018500894 A JP 2018500894A JP 2018520173 A JP2018520173 A JP 2018520173A
- Authority
- JP
- Japan
- Prior art keywords
- cholecalciferol sulfate
- cholecalciferol
- sulfate
- administration
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CAVKNZYPPDUUIT-YHJXBONMSA-N [(1r,3z)-3-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexyl] hydrogen sulfate Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@H](OS(O)(=O)=O)CCC1=C CAVKNZYPPDUUIT-YHJXBONMSA-N 0.000 title claims abstract description 76
- 206010047626 Vitamin D Deficiency Diseases 0.000 title 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 230000007812 deficiency Effects 0.000 claims abstract description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 18
- 235000019766 L-Lysine Nutrition 0.000 claims description 13
- 239000004472 Lysine Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 7
- 230000009885 systemic effect Effects 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 238000010255 intramuscular injection Methods 0.000 claims description 6
- 239000007927 intramuscular injection Substances 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000010254 subcutaneous injection Methods 0.000 claims description 6
- 239000007929 subcutaneous injection Substances 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 3
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 2
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 1
- 238000013269 sustained drug release Methods 0.000 claims 1
- 239000011647 vitamin D3 Substances 0.000 description 17
- 229940021056 vitamin d3 Drugs 0.000 description 17
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 16
- 235000005282 vitamin D3 Nutrition 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 238000009472 formulation Methods 0.000 description 8
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 150000001768 cations Chemical class 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000008399 tap water Substances 0.000 description 5
- 235000020679 tap water Nutrition 0.000 description 5
- FBPINGSGHKXIQA-UHFFFAOYSA-N 2-amino-3-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(N)CSCCC(O)=O FBPINGSGHKXIQA-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical class N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 0 C*[C@@](CCC1=C)CC1=CC=C(CCC1)[C@](CC2)[C@@]1(C)[C@]2[C@](C)CCCC(C)C Chemical compound C*[C@@](CCC1=C)CC1=CC=C(CCC1)[C@](CC2)[C@@]1(C)[C@]2[C@](C)CCCC(C)C 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- -1 cholecalciferol sulfates Chemical class 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- NKNFUMKGJYKPCT-UHFFFAOYSA-N n,n-diethylethanamine;sulfuric acid Chemical compound [O-]S([O-])(=O)=O.CC[NH+](CC)CC.CC[NH+](CC)CC NKNFUMKGJYKPCT-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- UWSCPROMPSAQOL-UHFFFAOYSA-N trimethylazanium;sulfate Chemical compound CN(C)C.CN(C)C.OS(O)(=O)=O UWSCPROMPSAQOL-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
コレカルシフェロール硫酸トリエチルアンモニウムの調製
ピリジン6.5mlを、窒素雰囲気下で、ピリジン-三酸化硫黄複合体1.21g(約6.76mmolの、SO3と複合体形成したピリジン; Sigma-Aldrich社;製造者による情報によれば、≧45wt.-% SO3)及びコレカルシフェロール(Sigma-Aldrich社)1.21g(3.14mmol)に添加した。得られた溶液を58℃で1時間、集中的に撹拌した。次いで、トリエチルアミン0.63ml(0.456g;4.55mmol)を添加し、撹拌を58℃で更に20分間継続した。
コレカルシフェロール硫酸アンモニウムの調製
飽和酢酸アンモニウム溶液約14mlをコレカルシフェロール硫酸トリエチルアンモニウム1.52g(3.13mmol)に、コレカルシフェロール硫酸アンモニウムの白色沈殿物が形成するまで添加し、これを、一晩放置した後、ガラスフリットを使用して濾過し、約15℃の温度の水道水により冷却しながら高真空下で乾燥させた。
収量:1.74g(3.10mmol、99%)。
融点:104〜108℃
コレカルシフェロール硫酸ナトリウムの調製
収量:1.75g(3.10mmol、99%)。
コレカルシフェロール硫酸マグネシウムの調製
塩化マグネシウムの飽和溶液(約13ml)をコレカルシフェロール硫酸トリエチルアンモニウム1.52g(3.13mmol)に、コレカルシフェロール硫酸マグネシウムの白色沈殿物が形成するまで添加し、これを、一晩放置した後、ガラスフリットを使用して濾過し、約15℃の温度を有する水道水により冷却しながら高真空下で乾燥させた。
収量:1.76g(3.10mmol;99%)。
融点:107〜110℃(分解)。
コレカルシフェロール硫酸カルシウムの調製
CaCl2・2H2Oの飽和溶液(約13ml)をコレカルシフェロール硫酸トリエチルアンモニウム1.52g(3.13mmol)に、コレカルシフェロール硫酸カルシウムの白色沈殿物が形成するまで添加し、これを、一晩放置した後、ガラスフリットを使用して濾過し、約15℃の温度を有する水道水により冷却しながら高真空下で乾燥させた。
収量:1.81g、(3.10mmol、99%)。
TLC(シリカゲル):Rf=メタノール-トリクロロメタン中(1:9Vol./Vol.)0.48
融点:97〜101℃(分解)。
コレカルシフェロール硫酸L-リジンの調製
TLC(シリカゲル):Rf=メタノール-トリクロロメタン(1:9Vol./Vol.)中0.33。
融点:168℃(分解)
コレカルシフェロール硫酸D,L-リジンの調製
コレカルシフェロール硫酸D,L-リジンの調製は、L-リジンの代わりにDL-リジン(Sigma-Aldrich社)を使用してコレカルシフェロール硫酸L-リジンの調製に類似したやり方で行った。
油性基剤中のコレカルシフェロール硫酸L-リジンの経皮製剤
コレカルシフェロール硫酸L-リジン100mgをオレイン酸11.04mlと混合し、次いでジメチルスルホキシド0.83mlを添加し、磁気撹拌機により室温(21〜25℃)で2日間撹拌した。引き続いて、トリオレイン酸グリセロール10ml及びモノオレイン酸グリセロール(Pecerol(登録商標)、Gattefosse社)7mlを添加し、活発に振盪した。混合物が消泡するまで待った後、油相中のコレカルシフェロール硫酸L-リジンのほぼ完全に透明な安定溶液を得た。
実施例8の経皮製剤の皮膚への塗布
実施例8で調製した製剤約2mlを対象の皮膚に薄層で塗布し、4時間浸透させた。引き続いて、皮膚を、96%エタノールに浸漬した滅菌綿パッドを使用して十分拭った。綿パッドを追加の96%エタノールとともに煮沸し、圧搾した。エタノールをロータリーエバポレーターで蒸発させ、少量のクロロホルム-メタノール(9:1Vol./Vol.)混合物をフラスコに添加した。シリカゲル上でのこの混合物のTLCにより、コレカルシフェロール硫酸L-リジン(Rf:0.33)は、皮膚上に実質的に残っていなかったことが示された。
水性注射液の調製
10,000IUのビタミンD3に対応する量でコレカルシフェロール硫酸塩を含有する注射液2mlを調製するために、
a)注射液Aを生成するためのコレカルシフェロール硫酸ナトリウム1.5695mg
b)注射液Bを生成するためのコレカルシフェロール硫酸カルシウム1.6243mg
及び
c)注射液Cを生成するためのコレカルシフェロール硫酸L-リジン1.970mg
を蒸留水10ml中にそれぞれ溶解させた。次いで塩化ナトリウム89.9028mgを溶液のそれぞれに添加してこれらを等張性にした。
Claims (12)
- 脊椎動物、特にヒトにおけるビタミンD3欠乏症と闘うための、コレカルシフェロールスルファートの薬学的に許容される塩の使用であって、前記コレカルシフェロールスルファートの塩の少なくとも5%が、代謝されることなく投与部位から人体の全身的流体輸送システムに入ることを可能にする投与方法による、使用。
- 前記投与方法が、経皮及び経粘膜投与、並びに持続薬物放出デポー注射を含む皮内、皮下及び筋肉内注射から選択される、請求項1に記載の使用。
- 前記コレカルシフェロールスルファートの塩が、コレカルシフェロール硫酸ナトリウム、コレカルシフェロール硫酸マグネシウム、コレカルシフェロール硫酸カルシウム、コレカルシフェロール硫酸アンモニウム、コレカルシフェロール硫酸トリメチルアンモニウム、及び/又はコレカルシフェロール硫酸L-リジンから選択される、請求項1に記載の使用。
- 前記コレカルシフェロールスルファートの塩が、コレカルシフェロール硫酸L-リジンである、請求項2に記載の使用。
- コレカルシフェロール硫酸ナトリウム、コレカルシフェロール硫酸アンモニウム、及びコレカルシフェロール硫酸トリメチルアンモニウムを除く、コレカルシフェロールスルファートの薬学的に許容される塩。
- コレカルシフェロール硫酸マグネシウム、コレカルシフェロール硫酸カルシウム、及びコレカルシフェロール硫酸L-リジンから選択される、請求項5に記載のコレカルシフェロールスルファートの薬学的に許容される塩。
- コレカルシフェロールスルファートの少なくとも1種の薬学的に許容される塩と、経皮若しくは経粘膜投与、又は持続放出デポー注射を含む皮内、皮下若しくは筋肉内注射に適したビヒクルとを含む医薬組成物。
- 前記ビヒクルが、経皮投与に適した油又は脂肪ベースのビヒクルである、請求項7に記載の医薬組成物。
- 前記ビヒクルが、経皮投与に適した水性又は水性アルコールビヒクルである、請求項7に記載の医薬組成物。
- パッチの形態である、請求項7から9のいずれか一項に記載の医薬組成物。
- 前記ビヒクルが、水性又は水性アルコールベースでの経粘膜投与に適したビヒクルである、請求項7に記載の医薬組成物。
- 前記ビヒクルが、皮内、皮下又は筋肉内注射に適した水性又は水性アルコールベースのビヒクルである、請求項7に記載の医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102015009022.4 | 2015-07-12 | ||
DE102015009022.4A DE102015009022A1 (de) | 2015-07-12 | 2015-07-12 | Neue Verwendung von Cholecalciferolsulfat-Salzen und neue Cholecalciferolsulfat-Salze |
DE102015014760.9A DE102015014760A1 (de) | 2015-11-15 | 2015-11-15 | Neue Verwendung von Cholecalciferolsulfat-Salzen |
DE102015014760.9 | 2015-11-15 | ||
PCT/EP2016/001201 WO2017008902A1 (de) | 2015-07-12 | 2016-07-12 | Cholecalciferolsulfat-salze und deren verwendung zur behandlung von vitamin d3-mangel |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020208442A Division JP2021042253A (ja) | 2015-07-12 | 2020-12-16 | コレカルシフェロール硫酸塩及びビタミンd欠乏症の処置のためのこれらの使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018520173A true JP2018520173A (ja) | 2018-07-26 |
JP6812405B2 JP6812405B2 (ja) | 2021-01-13 |
Family
ID=56611215
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018500894A Active JP6812405B2 (ja) | 2015-07-12 | 2016-07-12 | コレカルシフェロール硫酸塩及びビタミンd欠乏症の処置のためのこれらの使用 |
JP2020208442A Pending JP2021042253A (ja) | 2015-07-12 | 2020-12-16 | コレカルシフェロール硫酸塩及びビタミンd欠乏症の処置のためのこれらの使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020208442A Pending JP2021042253A (ja) | 2015-07-12 | 2020-12-16 | コレカルシフェロール硫酸塩及びビタミンd欠乏症の処置のためのこれらの使用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US11819507B2 (ja) |
EP (1) | EP3328390B1 (ja) |
JP (2) | JP6812405B2 (ja) |
CN (2) | CN112516151B (ja) |
AU (1) | AU2016293240B2 (ja) |
CA (1) | CA2992137C (ja) |
DE (1) | DE112016003135A5 (ja) |
DK (1) | DK3328390T3 (ja) |
EA (1) | EA201890281A1 (ja) |
ES (1) | ES2904405T3 (ja) |
NZ (1) | NZ739679A (ja) |
PL (1) | PL3328390T3 (ja) |
WO (1) | WO2017008902A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201900014550A1 (it) * | 2019-08-09 | 2021-02-09 | Abiogen Pharma Spa | Uso di colecalciferolo come agente attivo nel trattamento della celiachia |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2296291A (en) * | 1938-04-02 | 1942-09-22 | Research Corp | Water soluble derivative of vitamin d |
US2584731A (en) * | 1950-05-25 | 1952-02-05 | Ajinomoto Kk | Manufacturing method of solid l-monosodium glutamate monohydrate |
US2791606A (en) * | 1954-06-07 | 1957-05-07 | Ohio Commw Eng Co | Synthesis of glutamic acid and salts thereof |
US3139378A (en) * | 1959-05-19 | 1964-06-30 | Corn Products Co | Method of making calcium sorbate |
DE1443871A1 (de) * | 1963-12-12 | 1968-12-19 | Hoechst Ag | Verfahren zur Herstellung von Calciumsorbat |
NL127988C (ja) * | 1965-06-04 | |||
US3989822A (en) * | 1974-02-14 | 1976-11-02 | Purdue Research Foundation | Weight control compound |
US4588528A (en) * | 1984-05-31 | 1986-05-13 | Wisconsin Alumni Research Foundation | 1,24-dihydroxy-Δ22 -vitamin D3 and process for preparing same |
US5422127A (en) * | 1992-12-21 | 1995-06-06 | Bristol-Myers Squibb Company | Nutritional compositions containing vitamin D esters |
US5478816A (en) * | 1993-07-02 | 1995-12-26 | Bristol-Myers Squibb Company | Liquid vitamin formulations containing vitamin D esters |
CN1221736A (zh) * | 1998-09-14 | 1999-07-07 | 孙伟燕 | 制备1α,25-二羟基维生素Da药物及类似物的方法 |
UY27505A1 (es) * | 2001-10-23 | 2003-06-30 | Boehringer Ingelheim Int | Tableta masticable que contiene lisina |
US20050192255A1 (en) * | 2003-07-30 | 2005-09-01 | Jin Tian | Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease |
EP2647371A1 (en) * | 2008-06-19 | 2013-10-09 | University Of The Witwatersrand Johannesburg | A transmucosal delivery system |
US20110152207A1 (en) * | 2009-12-23 | 2011-06-23 | Goff Jesse P | Use of vitamin d glycosides and sulfates for treatment of disease |
RS59067B1 (sr) * | 2013-12-04 | 2019-09-30 | Galmed Res & Development Ltd | Soli aramchol-a |
-
2016
- 2016-07-12 CN CN202011450425.4A patent/CN112516151B/zh active Active
- 2016-07-12 NZ NZ739679A patent/NZ739679A/en unknown
- 2016-07-12 CA CA2992137A patent/CA2992137C/en active Active
- 2016-07-12 DK DK16748057.3T patent/DK3328390T3/da active
- 2016-07-12 AU AU2016293240A patent/AU2016293240B2/en active Active
- 2016-07-12 EA EA201890281A patent/EA201890281A1/ru unknown
- 2016-07-12 DE DE112016003135.1T patent/DE112016003135A5/de not_active Withdrawn
- 2016-07-12 JP JP2018500894A patent/JP6812405B2/ja active Active
- 2016-07-12 ES ES16748057T patent/ES2904405T3/es active Active
- 2016-07-12 EP EP16748057.3A patent/EP3328390B1/de active Active
- 2016-07-12 CN CN201680051947.2A patent/CN108337879B/zh active Active
- 2016-07-12 WO PCT/EP2016/001201 patent/WO2017008902A1/de active Application Filing
- 2016-07-12 PL PL16748057T patent/PL3328390T3/pl unknown
- 2016-07-12 US US15/743,327 patent/US11819507B2/en active Active
-
2020
- 2020-12-16 JP JP2020208442A patent/JP2021042253A/ja active Pending
Non-Patent Citations (4)
Title |
---|
BOULCH N L; CANCELA L; MIRAVET L: "CHOLECALCIFEROL SULFATE IDENTIFICATION IN HUMAN MILK BY HPLC", STEROIDS, vol. VOL:39, NR:4, JPN5018004528, April 1982 (1982-04-01), US, pages 391 - 398, ISSN: 0004253797 * |
CANCELA L: ET AL: "LACK OF BIOLOGICAL ACTIVITY OF VITAMIN D3-3β SULFATE DURING LACTATION IN VITAMIN D-DEFICIENT RATS", REPRODUCTION, NUTRITION, DEVELOPMENT, vol. V27 N6, JPN5018004527, 1987, FR, pages 979 - 997, ISSN: 0004253796 * |
PERRINE CG; ET AL: "ADHERENCE TO VITAMIN D RECOMMENDATIONS AMONG US INFANTS", PEDIATRICS, vol. V125 N4, JPN5018004525, April 2010 (2010-04-01), US, pages 627 - 632, ISSN: 0004253795 * |
SREERAMULU NAGUBANDI; ET AL: "SYNTHESIS AND BIOLOGICAL ACTIVITY OF VITAMIN D3, 3β-SULFATE", THE JOURNAL OF BLOLVCICAL CHEMISTRY, vol. V256 N11, JPN5018004526, 10 June 1981 (1981-06-10), pages 5536 - 5539, ISSN: 0004253794 * |
Also Published As
Publication number | Publication date |
---|---|
AU2016293240B2 (en) | 2021-02-04 |
AU2016293240A1 (en) | 2018-03-01 |
CN112516151A (zh) | 2021-03-19 |
CN108337879B (zh) | 2021-01-19 |
EP3328390B1 (de) | 2021-09-29 |
JP6812405B2 (ja) | 2021-01-13 |
NZ739679A (en) | 2022-02-25 |
JP2021042253A (ja) | 2021-03-18 |
EA201890281A1 (ru) | 2018-07-31 |
PL3328390T3 (pl) | 2022-03-28 |
DE112016003135A5 (de) | 2018-08-30 |
US20180200269A1 (en) | 2018-07-19 |
CA2992137C (en) | 2023-09-12 |
CN108337879A (zh) | 2018-07-27 |
EP3328390A1 (de) | 2018-06-06 |
US11819507B2 (en) | 2023-11-21 |
CN112516151B (zh) | 2024-06-28 |
ES2904405T3 (es) | 2022-04-04 |
CA2992137A1 (en) | 2017-01-19 |
WO2017008902A1 (de) | 2017-01-19 |
DK3328390T3 (da) | 2022-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60118019T2 (de) | Zusammensetzung enthaltend hydroxyzitronensäure und garcinol zur gewichtsreduzierung | |
JP2001512487A (ja) | 抗細胞増殖剤のゲル送出ベヒクル | |
JPH09508349A (ja) | 安定化オルトケイ酸含有調製物および生物学的調製物 | |
JP2020503357A5 (ja) | ||
WO1996015793A1 (fr) | Preparation absorbable par voie percutanee | |
CA2722578C (en) | Use of .delta.-amino levulinic acid to treat male infertility | |
US20140004177A1 (en) | Cox-2 inhibitors and related compounds, and systems and methods for delivery thereof | |
JP2019526634A5 (ja) | ||
KR20030092082A (ko) | 활성 성분으로 조효소 q를 함유하는 경점막 투여용 조성물 | |
JP2020534272A (ja) | 経皮製剤 | |
JP2021042253A (ja) | コレカルシフェロール硫酸塩及びビタミンd欠乏症の処置のためのこれらの使用 | |
JP2002514584A (ja) | 治療組成物 | |
CA2506298C (en) | Conjugated fatty acid based emulsion and methods for preparing and using same | |
JPS6041656A (ja) | 新規アミノ酸誘導体の製法 | |
WO2015055974A1 (en) | Proton pump inhibitor paste compositions | |
EA043805B1 (ru) | Новое применение сернокислых солей холекальциферола и новые сернокислые соли холекальциферола | |
CZ300305B6 (cs) | Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností | |
JP2020535211A (ja) | 医療用葉酸塩 | |
EP0766692B1 (fr) | Derives de l'acide guanylique et applications comme medicaments | |
DE102015009022A1 (de) | Neue Verwendung von Cholecalciferolsulfat-Salzen und neue Cholecalciferolsulfat-Salze | |
CA2193096C (fr) | Derives de l'acide guanylique et applications comme medicaments | |
JP2007191417A (ja) | 医薬用の組成物 | |
US20090137656A1 (en) | Intermolecular Association Complex of a Carrier and of an Active Principle | |
CH347531A (de) | Verfahren zur Herstellung einer bakteriostatisch bis baktericid wirkenden Verbindung der Ascorbinsäure | |
EP1857460A2 (fr) | Nouveaux complexes métalliques, procédé pour leur préparation et leur utilisation thérapeutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190619 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200420 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200720 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201020 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201021 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201216 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6812405 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |